Effect of Melatonin in treatment of COVID-19
Phase 3
Recruiting
- Conditions
- Covid-19.covid-19U07.1
- Registration Number
- IRCT20200426047206N4
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Age between 18-75 year
Hospitalized in ward
Confirmed diagnosis with PCR
Elapsed less than 48 hour from symptom onset
Not pregnant or breastfeeding
Do not have moderate to severe liver and renal problems.
Not treated with immunosuppressive drugs during the last 3 months
Exclusion Criteria
Drug intolerance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eed to oxygen therapy rate. Timepoint: During treatment. Method of measurement: view patients medical file.;Rate of sleep and depression. Timepoint: Hospital Anxiety and Depression Questionnaire. Method of measurement: Score.;The amount of hospitalization in the intensive care unit during 28 days. Timepoint: Day 28 after treatment. Method of measurement: view patients medical file.
- Secondary Outcome Measures
Name Time Method